The introduction of BRAF inhibitors marked a significant advancement in the management of advanced melanoma, highlighting the critical role of the BRAF and MEK proteins in melanoma pathogenesis through their involvement in the mitogen-activated protein kinase (MAPK) pathway [21]. The gene discussed is MAP2K7; the disease is melanoma.